{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:51:58Z","timestamp":1791420718769,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82172913"],"award-info":[{"award-number":["No. 82172913"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z221100007422109"],"award-info":[{"award-number":["Z221100007422109"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clear cell renal cell carcinoma (ccRCC) exhibits glycolytic addiction due to VHL mutation, making it vulnerable to metabolic intervention. While conventional inhibitors targeting core housekeeping glycolytic enzymes show robust antitumor efficacy, their clinical use is limited by on-target systemic toxicity. Here, we identify enolase 2 (ENO2) as an isoform-specific glycolytic vulnerability specific to VHL-deficient ccRCC. Although ENO2 is physiologically redundant (compensated by ENO1) in normal glycolysis, it becomes essential for sustaining ccRCC malignancy via VHL loss-HIF2\u03b1-driven glycolytic flux. Targeting ENO2 specifically suppressed glycolysis in VHL-deficient ccRCC cells, reducing their malignancy and enhancing their response to axitinib, doxorubicin, and gemcitabine. Importantly, pharmacological ENO2 blockade displayed superior tumor selectivity compared to traditional glycolysis inhibitors, effectively eliminating VHL-deficient ccRCC cells while sparing VHL-intact normal and malignant cells, despite causing slightly weaker glycolytic suppression. Mechanistic investigations revealed that ENO2 ablation inactivated up to ~78% of VHL loss-induced oncogenic effectors, including a pleiotropic oncoprotein MDK, through dual modulation of lactate metabolism and interferon signaling. Collectively, this work reveals ENO2 as a genotype-specific metabolic dependency in ccRCC, thereby enabling precision glycolytic therapy. Our work also suggests that targeting physiologically redundant metabolic isoenzymes may offer a precision medicine strategy for cancers with defined genetic alterations.<\/jats:p>","DOI":"10.1038\/s41419-026-09102-4","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:53:51Z","timestamp":1784019231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-4460","authenticated-orcid":false,"given":"Jiannan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5907-6880","authenticated-orcid":false,"given":"Xuying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-4801","authenticated-orcid":false,"given":"Haili","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0675-0163","authenticated-orcid":false,"given":"Tao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-8446","authenticated-orcid":false,"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"9102_CR1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet (Lond, Engl). 2009;373:1119\u201332.","journal-title":"Lancet (Lond, Engl)"},{"key":"9102_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41581-023-00800-2","volume":"20","author":"NJ Coffey","year":"2024","unstructured":"Coffey NJ, Simon MC. Metabolic alterations in hereditary and sporadic renal cell carcinoma. Nat Rev Nephrol. 2024;20:233\u201350.","journal-title":"Nat Rev Nephrol"},{"key":"9102_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneph.2017.59","volume":"13","author":"HI Wettersten","year":"2017","unstructured":"Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017;13:410\u20139.","journal-title":"Nat Rev Nephrol"},{"key":"9102_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrurol.2010.47","volume":"7","author":"WM Linehan","year":"2010","unstructured":"Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277\u201385.","journal-title":"Nat Rev Urol"},{"key":"9102_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.cmet.2018.07.020","volume":"28","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, et al. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metab. 2018;28:793\u2013800.e2.","journal-title":"Cell Metab"},{"key":"9102_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41419-024-06913-1","volume":"15","author":"SC Di","year":"2024","unstructured":"Di SC, Chen WJ, Yang W, Zhang XM, Dong KQ, Tian YJ, et al. DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT\/mTOR\/HIF1\u03b1 pathway. Cell Death Dis. 2024;15:533.","journal-title":"Cell Death Dis"},{"key":"9102_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.","journal-title":"Nat Rev Dis Prim"},{"key":"9102_CR8","doi-asserted-by":"crossref","unstructured":"Rathmell WK, Rathmell JC, Linehan WM. Metabolic pathways in kidney cancer: current therapies and future directions. J Clin Oncol. 2018;36:3540\u201346.","DOI":"10.1200\/JCO.2018.79.2309"},{"key":"9102_CR9","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519\u201330.","journal-title":"Nat Med"},{"key":"9102_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"9102_CR11","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633\u201346.","journal-title":"Oncogene"},{"key":"9102_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol cancer. 2013;12:152.","journal-title":"Mol cancer"},{"key":"9102_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161\u201380.","journal-title":"Cell Chem Biol"},{"key":"9102_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrc.2016.77","volume":"16","author":"N Hay","year":"2016","unstructured":"Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16:635\u201349.","journal-title":"Nat Rev Cancer"},{"key":"9102_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703\u20137.","journal-title":"Cell"},{"key":"9102_CR16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","volume":"107","author":"A Le","year":"2010","unstructured":"Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010;107:2037\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9102_CR17","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/0008-5472.CAN-21-3983","volume":"82","author":"M Marczyk","year":"2022","unstructured":"Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, et al. Comprehensive analysis of metabolic isozyme targets in cancer. Cancer Res. 2022;82:1698\u2013711.","journal-title":"Cancer Res"},{"key":"9102_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.molcel.2015.11.005","volume":"60","author":"E Balsa-Martinez","year":"2015","unstructured":"Balsa-Martinez E, Puigserver P. Cancer cells hijack gluconeogenic enzymes to fuel cell growth. Mol Cell. 2015;60:509\u201311.","journal-title":"Mol Cell"},{"key":"9102_CR19","unstructured":"The Genotype-Tissue Expression (GTEx) project. Nature genetics. 2013;45:580\u20135."},{"key":"9102_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41419-020-03179-1","volume":"11","author":"K Jiang","year":"2020","unstructured":"Jiang K, Dong C, Yin Z, Li R, Mao J, Wang C, et al. Exosome-derived ENO1 regulates integrin \u03b16\u03b24 expression and promotes hepatocellular carcinoma growth and metastasis. Cell Death Dis. 2020;11:972.","journal-title":"Cell Death Dis"},{"key":"9102_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/bio.2015.29031.hmm","volume":"13","author":"LJ Carithers","year":"2015","unstructured":"Carithers LJ, Moore HM. The genotype-tissue expression (GTEx) project. Biopreserv Biobanking. 2015;13:307\u20138.","journal-title":"Biopreserv Biobanking"},{"key":"9102_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature11331","volume":"488","author":"FL Muller","year":"2012","unstructured":"Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012;488:337\u201342.","journal-title":"Nature"},{"key":"9102_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0140-6736(81)92682-9","volume":"1","author":"FJ Tapia","year":"1981","unstructured":"Tapia FJ, Polak JM, Barbosa AJ, Bloom SR, Marangos PJ, Dermody C, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet (Lond, Engl). 1981;1:808\u201311.","journal-title":"Lancet (Lond, Engl)"},{"key":"9102_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s42255-020-00313-3","volume":"2","author":"YH Lin","year":"2020","unstructured":"Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020;2:1413\u201326.","journal-title":"Nat Metab"},{"key":"9102_CR25","doi-asserted-by":"crossref","unstructured":"Liao L, Liu ZZ, Langbein L, Cai W, Cho EA, Na J, et al. Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer. eLife. 2018;7:e37925.","DOI":"10.7554\/eLife.37925"},{"key":"9102_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574:575\u201380.","journal-title":"Nature"},{"key":"9102_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.885656","volume":"12","author":"L Zheng","year":"2022","unstructured":"Zheng L, Liu Q, Li R, Chen S, Tan J, Li L, et al. Targeting MDK abrogates IFN-\u03b3-elicited metastasis incancers of various origins. Front Oncol. 2022;12:885656.","journal-title":"Front Oncol"},{"key":"9102_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci (N Y, NY). 2009;324:1029\u201333.","journal-title":"Sci (N Y, NY)"},{"key":"9102_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211\u20138.","journal-title":"Trends Biochem Sci"},{"key":"9102_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resistance Updates. 2018;38:1\u201311.","journal-title":"Drug Resistance Updates"},{"key":"9102_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-022-01358-5","volume":"15","author":"X Zhong","year":"2022","unstructured":"Zhong X, He X, Wang Y, Hu Z, Huang H, Zhao S, et al. Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications. J Hematol Oncol. 2022;15:160.","journal-title":"J Hematol Oncol"},{"key":"9102_CR32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","volume":"14","author":"M Liao","year":"2024","unstructured":"Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J, et al. Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharma Sin B. 2024;14:953\u20131008.","journal-title":"Acta Pharma Sin B"},{"key":"9102_CR33","doi-asserted-by":"crossref","unstructured":"Chen WJ, Yang W, Gong M, He Y, Xu D, Chen JX, et al. ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment. Oncol Rep. 2023;49:33.","DOI":"10.3892\/or.2022.8470"},{"key":"9102_CR34","doi-asserted-by":"crossref","unstructured":"Shi J, Miao D, Lv Q, Tan D, Xiong Z, Zhang X. ENO2 as a biomarker regulating energy metabolism to promote tumor progression in clear cell renal cell carcinoma. Biomedicines. 2023;11:2499.","DOI":"10.3390\/biomedicines11092499"},{"key":"9102_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1167\/iovs.66.1.58","volume":"66","author":"D Liao","year":"2025","unstructured":"Liao D, Wang J, Zhang X, Li R, Yang X. ENO2-regulated glycolysis in endothelial cells contributes to FGF2-induced retinal neovascularization. Investig Ophthalmol Vis Sci. 2025;66:58.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"9102_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-022-01693-z","volume":"21","author":"M Yang","year":"2022","unstructured":"Yang M, Wu S, Cai W, Ming X, Zhou Y, Chen X. Hypoxia-induced MIF induces dysregulation of lipid metabolism in Hep2 laryngocarcinoma through the IL-6\/JAK-STAT pathway. Lipids Health Dis. 2022;21:82.","journal-title":"Lipids Health Dis"},{"key":"9102_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41418-024-01271-z","volume":"31","author":"H Chen","year":"2024","unstructured":"Chen H, Yu S, Ma R, Deng L, Yi Y, Niu M, et al. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of \u0394Np63\u03b1 expression and promote breast cancer metastasis independent of HIF1\u03b1. Cell Death Differ. 2024;31:447\u201359.","journal-title":"Cell Death Differ"},{"key":"9102_CR38","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41388-019-1124-8","volume":"39","author":"PS Filippou","year":"2020","unstructured":"Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39:2040\u201354.","journal-title":"Oncogene"},{"key":"9102_CR39","doi-asserted-by":"crossref","unstructured":"Saikia M, Cheung N, Singh AK, Kapoor V. Role of midkine in cancer drug resistance: regulators of its expression and its molecular targeting. Int J Mol Sci. 2023;24:8739.","DOI":"10.3390\/ijms24108739"},{"key":"9102_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2011.10.013","volume":"316","author":"T Sueyoshi","year":"2012","unstructured":"Sueyoshi T, Jono H, Shinriki S, Ota K, Ota T, Tasaki M, et al. Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma. Cancer Lett. 2012;316:23\u201330.","journal-title":"Cancer Lett"},{"key":"9102_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32673-7","volume":"13","author":"Y Tang","year":"2022","unstructured":"Tang Y, Kwiatkowski DJ, Henske EP. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment. Nat Commun. 2022;13:5018.","journal-title":"Nat Commun"},{"key":"9102_CR42","doi-asserted-by":"publisher","first-page":"37124","DOI":"10.1074\/jbc.M405254200","volume":"279","author":"PR Reynolds","year":"2004","unstructured":"Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem. 2004;279:37124\u201332.","journal-title":"J Biol Chem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09102-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09102-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:29:38Z","timestamp":1791419378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09102-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9102"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09102-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"13 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"872"}}